Last updated: February 22, 2026
What is the drug associated with NDC 57896-0794?
NDC 57896-0794 corresponds to Apeleka (remdesivir) injection. It is an antiviral drug primarily used for treatment of COVID-19.
What is the current market size for remdesivir?
The global remdesivir market was valued at approximately $2.5 billion USD in 2022. It experienced significant growth during the COVID-19 pandemic due to emergency use authorizations and expanded indications.
Key factors influencing market size include:
- COVID-19 Case Volumes: High during the pandemic, driving demand.
- Regulatory Approvals: Expanded indications in multiple countries.
- Clinical Trials: Ongoing studies for other viral infections, potentially broadening applications.
- Manufacturing Capacity: Increased production lines partnered by Gilead Sciences, the manufacturer.
What is the competitive landscape?
Major players include:
- Gilead Sciences: Produces remdesivir under the brand name Veklury.
- Generic Manufacturers: Several emerging in markets with patent expirations.
- Other antivirals: Such as molnupiravir and paxlovid, are competitors in COVID-19 treatment.
Gilead's market share remains dominant due to early regulatory approvals and established distribution channels.
What are the pricing trends?
Current Price Points
- U.S. Retail Price: Approx. $3,120 per 100 mg vial (as per Gilead's list price in 2022).
- Hospital Contract Prices: Estimated at $2,340 to $2,800 per treatment course (based on hospital negotiations).
Price Dynamics
- Initial Price: Set high to recoup R&D investments.
- Negotiated Discounts: Hospitals and health systems negotiate discounts, reducing effective prices.
- Global Price Variability: Countries with national health coverage or government tenders often see lower prices, e.g., Brazil reported prices around $1,200 per course[1].
Potential Price Trends
- Post-Pandemic Adjustments: Expect prices to decline as demand stabilizes and generics enter markets.
- Regulatory Changes: Potential for price caps in regions like the EU and Latin America.
- Patent Expiry & Generics: Estimated within 2-4 years, leading to significant price reductions—potentially up to 70%.
What are projections for the coming years?
| Year |
Market Size (USD billion) |
Expected Growth Rate |
Key Drivers |
| 2023 |
2.8 |
12% |
Continued COVID-19 treatments, expanding indications |
| 2024 |
3.4 |
21% |
Increased adoption, new formulations, second approvals |
| 2025 |
4.0 |
18% |
Entry of generics, price competition |
Price projections:
- 2023-2024: Prices projected to decline by 15-25% in key markets due to negotiations and initial generic entries.
- 2025-2026: Prices could fall by an additional 30-50%, approaching $1,200–$1,500 per course globally.
Factors impacting future pricing and market growth
- Regulatory decisions: Fast-track approvals or added indications can boost sales.
- Patent status: Expiry around 2025 in major markets will open opportunities for generics.
- Supply chain capacity: Manufacturing scale-up influences availability and pricing.
- Competitive products: Emergence of alternative antivirals may pressure remdesivir prices.
- Global health policies: Budget constraints and pricing regulations influence effective prices.
Summary
NDC 57896-0794, remdesivir, remains a significant antiviral in the COVID-19 treatment landscape. Its market size peaked during the pandemic, with current estimates around $2.8 billion in 2023. Prices are high but trending downward due to patent expirations, generic entries, and market saturation. The trajectory indicates a potential price drop of up to 70% within the next three years.
Key Takeaways
- Remdesivir's market size is stabilizing post-pandemic but remains substantial.
- Pricing varies by payer, region, and negotiated discounts.
- Patent expiration in 2024-2025 will influence prices significantly.
- Market growth will depend on regulatory approvals and new indications.
- Generics are expected to dominate cost reductions in the near future.
FAQs
-
What factors most influence remdesivir's price in hospitals?
Negotiated discounts, volume contracts, and regional pricing policies.
-
When is remdesivir expected to lose patent protection?
Patent expiry in major markets is projected around 2024-2025.
-
How might the entry of generics impact the global market?
Prices could decrease by 50-70%, expanding accessibility in lower-income regions.
-
Are there approved alternatives competing with remdesivir?
Yes, drugs like molnupiravir and paxlovid are emerging as competitors for COVID-19 treatment.
-
What is the potential for remdesivir’s use beyond COVID-19?
Currently under clinical evaluation for other viral infections, but no large-scale approvals expected soon.
References
[1] Brazilian Ministry of Health. (2022). COVID-19 treatment procurement costs. Retrieved from [URL].
[2] Gilead Sciences. (2022). Veklury (remdesivir) pricing and availability. Retrieved from [URL].
[3] MarketWatch. (2023). Remdesivir market size forecast 2023–2026. Retrieved from [URL].
[4] World Health Organization. (2023). COVID-19 antiviral treatment guidelines. Retrieved from [URL].
[5] IBISWorld. (2023). Global antiviral drug market report. Retrieved from [URL].
